Classification of breast carcinomas into subtypes according to the expression of molecular markers, mainly ER, PR and HER-2, brought highly significant correlations with clinical outcomes, including overall survival and recurrence free survival68,69. This evidence concerns the gene ESR1 and breast carcinoma.